愛污传媒

Skip to main content

Pfizer buys Seagen for US$43B, boosts access to cancer drugs

A woman pushes a baby in a stroller past a sign hanging outside Pfizer headquarters in New York, May 23, 2022.  (AP Photo/Mary Altaffer) A woman pushes a baby in a stroller past a sign hanging outside Pfizer headquarters in New York, May 23, 2022. (AP Photo/Mary Altaffer)
Share

Pfizer is spending about US$43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.

The pharmaceutical giant said Monday it will pay US$229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug developer "continue innovating," except with more resources than it would have alone, Pfizer Chairman and CEO Albert Bourla told analysts.

"We are not buying the golden eggs," he said. "We are acquiring the goose that is laying the golden eggs."

Bothell, Washington-based Seagen Inc. specializes in working with antibody-drug conjugate, or ADC, technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding tissue.

Cancer treatments are a priority for Pfizer. They brought in US$12 billion in revenue for the drugmaker last year. But Pfizer has only marketed a couple first-generation ADC treatments, a spokeswoman said.

Seagen has four treatments on the market. It also has a pipeline of drugs under development that includes potential treatments for a form of lung cancer and advanced breast cancer.

"We think this really changes dramatically the oncology presence of Pfizer, makes it one of a kind," Bourla said.

Seagen's top seller, Adcetris, treats lymph system cancers. It brought in US$839 million in sales last year, a 19% increase over the previous year.

Seagen also has a deal with Pfizer's Array BioPharma to develop, make and sell the breast and colorectal cancer treatment Tukysa. It brought in $353 million in sales for Seagen last year.

The company, which changed its name from Seattle Genetics in 2020, saw total revenue grow about 25% last year to nearly $2 billion. Seagen also shaved its loss to US$610 million from $674 million in 2021.

The drug developer predicts about US$2.2 billion in sales for this year.

Pfizer booked about US$100 billion in total revenue last year and has been flush with cash thanks to sales of its COVID-19 vaccine and treatment, Comirnaty and Paxlovid.

Bourla said earlier this year that the company planned to use its "extraordinary firepower" to buy products that will deliver US$25 billion in incremental revenue by 2030.

The deal announced Monday and some previous acquisitions will help Pfizer account for most of that. But Bourla emphasized on Monday that the company expects Seagen's contributions to extend beyond the end of the decade.

New York-based Pfizer Inc. has already spent US$11.6 billion on migraine treatment developer Biohaven Pharmaceutical. It also spent $5.4 billion on sickle cell disease treatment maker Global Blood Therapeutics and bought Arena Pharmaceuticals for another $6.7 billion.

The drugmaker needs more revenue sources in part because it faces the expiration of patents protecting drugs like its breast cancer treatment Ibrance from cheaper competition in the coming years.

Pfizer said Monday it will pay for Seagen mostly through US$31 billion in new, long-term debt.

Both companies' boards have unanimously approved the deal. But regulators still need to look at it, and Seagen shareholders will have to approve it.

The companies expect to complete the transaction in late 2023 or early 2024.

Shares of Pfizer rose 2% to US$40.26 after markets opened Monday, while Seagen's stock soared more than 15% to nearly $200. Broader indexes edged up slightly.

CTVNews.ca Top Stories

BREAKING

BREAKING

The ongoing count of absentee ballots in B.C.鈥檚 nail-biting 2024 provincial election has put the NDP ahead of the Conservatives in the Surrey-Guildford riding.

A group of Cape Breton firefighters are apologizing after four people showed up at a Halloween dance dressed in what appeared to be Ku Klux Klan costumes.

Marred by several delays, the trial of alleged human traffickers Lauriston and Amber Maloney is underway Monday in a Bradford courtroom, with both entering a not guilty plea.

Local Spotlight

Epcor says it has removed more than 20,000 goldfish from an Edmonton stormwater pond.

Witches and warlocks have been flocking to New Brunswick waterways this month, as a new Halloween tradition ripples across the province.

New Brunswicker Jillea Godin鈥檚 elaborate cosplay pieces attract thousands to her online accounts, as well as requests from celebrities for their own pieces.

A new resident at a Manitoba animal rescue has waddled her way into people's hearts.

Hundreds of people ran to the music of German composer and pianist Beethoven Wednesday night in a unique race in Halifax.

He is a familiar face to residents of a neighbourhood just west of Roncesvalles Avenue.

A meteor lit up our region's sky last night 鈥 with a large fireball shooting across the horizon over Lake Erie at around 7:00 p.m.

Residents of Ottawa's Rideauview neighbourhood say an aggressive wild turkey has become a problem.

A man who lost his life while trying to rescue people from floodwaters, and a 13-year-old boy who saved his family from a dog attack, are among the Nova Scotians who received a medal for bravery Tuesday.

Stay Connected